About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Molecular Connection Between Obesity and Insulin Resistance Brings Hope of Safer Diabetes Drugs

by Savitha C Muppala on July 26, 2010 at 11:27 AM
Font : A-A+

 New Molecular Connection Between Obesity and Insulin Resistance Brings Hope of Safer Diabetes Drugs

Researchers have discovered a new molecular link between obesity and the way diabetes drugs work , which may lead to the development of safer medications for diabetes.

Scientists from Dana-Farber Cancer Institute and The Scripps Research Institute, led by Dr. Bruce Spiegelman, conducted the above study.

Advertisement

"Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism," Nature quoted Spiegelman as saying.

Avandia and Actos, known generically as rosiglitazone and pioglitazone, are widely used to counteract the obesity-related abnormalities in insulin response that lead to diabetes.
Advertisement

The drugs act on a master regulatory protein called PPAR-gamma, primarily in fat cells, which governs genes involved in the body's response to insulin.

Obesity resulting from a high-fat diet alters the function of PPAR-gamma and disrupts the expression of those insulin response genes, including adipsin and adiponectin.

Avandia and Actos work by binding to PPAR-gamma and reversing the gene expression changes.

The drugs were believed to work by stimulating or "agonizing" the PPAR-gamma receptor, causing it to rev up some genes and dampen the activity of others.

However, in the new study, researchers say that they have identified "an entirely new and surprising mechanism by which PPAR-gamma can control whole-body insulin sensitivity."

They found that it is mainly through this mechanism that the diabetes drugs counteract insulin resistance - not their agonist effect on PPAR-gamma.

Moreover, they say, agonism of PPAR-gamma may be largely responsible for the harmful drug side effects.

The newly identified pathway linking obesity and insulin response involves cdk5, a protein kinase, or molecular "switch."

When cdk5 is activated by the development of obesity in mice, it causes a chemical change in PPAR-gamma called phosphorylation.

In contrast to agonism of PPAR-gamma, phosphorylation has a narrow effect, disrupting a smaller set of genes that lead to insulin resistance.

In addition to agonizing PPAR-gamma, Avandia and Actos also block the phosphorylation of PPAR-gamma by cdk5.

It's this latter effect that accounts for most of the drugs' anti-diabetic benefits, the authors contend.

The study has been published in the latest issue of Nature.

Source: ANI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Bariatric Surgery Diabetic Retinopathy Drug Toxicity Obesity Diabetes Diabetic Diet Diabetes - Essentials Bulimia Nervosa Diabetes - Self-Monitoring of Blood Glucose (SMBG) Insulin Delivery Devices 

Most Popular on Medindia

Selfie Addiction Calculator Turmeric Powder - Health Benefits, Uses & Side Effects Accident and Trauma Care Find a Doctor Blood Pressure Calculator Noscaphene (Noscapine) Calculate Ideal Weight for Infants Blood Donation - Recipients Sinopril (2mg) (Lacidipine) Daily Calorie Requirements
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

New Molecular Connection Between Obesity and Insulin Resistance Brings Hope of Safer Diabetes Drugs Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests